155 related articles for article (PubMed ID: 17923830)
1. Effects of hormonal therapy on cognitive functioning in breast cancer patients: a review of the literature.
Schilder CM; Schagen SB
Minerva Ginecol; 2007 Aug; 59(4):387-401. PubMed ID: 17923830
[TBL] [Abstract][Full Text] [Related]
2. [The effect of hormone therapy on cognitive function in patients with breast cancer].
Schilder CM; Linn SC; van Dam FS; Schagen SB
Ned Tijdschr Geneeskd; 2008 Mar; 152(9):494-8. PubMed ID: 18389880
[TBL] [Abstract][Full Text] [Related]
3. Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients: results of a multicenter, prospective, longitudinal study.
Hermelink K; Henschel V; Untch M; Bauerfeind I; Lux MP; Munzel K
Cancer; 2008 Nov; 113(9):2431-9. PubMed ID: 18823033
[TBL] [Abstract][Full Text] [Related]
4. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study.
Jenkins V; Shilling V; Fallowfield L; Howell A; Hutton S
Psychooncology; 2004 Jan; 13(1):61-6. PubMed ID: 14745746
[TBL] [Abstract][Full Text] [Related]
5. Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
Collins B; Mackenzie J; Stewart A; Bielajew C; Verma S
Psychooncology; 2009 Aug; 18(8):811-21. PubMed ID: 19085975
[TBL] [Abstract][Full Text] [Related]
6. The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer.
Banerjee S; Pancholi S; A'hern R; Ghazoui Z; Smith IE; Dowsett M; Martin LA
Clin Cancer Res; 2008 May; 14(9):2656-63. PubMed ID: 18451229
[TBL] [Abstract][Full Text] [Related]
7. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Carpenter R
Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
[TBL] [Abstract][Full Text] [Related]
8. Is basic research providing answers if adjuvant anti-estrogen treatment of breast cancer can induce cognitive impairment?
Buwalda B; Schagen SB
Life Sci; 2013 Oct; 93(17):581-8. PubMed ID: 23353876
[TBL] [Abstract][Full Text] [Related]
9. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen.
Castellon SA; Ganz PA; Bower JE; Petersen L; Abraham L; Greendale GA
J Clin Exp Neuropsychol; 2004 Oct; 26(7):955-69. PubMed ID: 15742545
[TBL] [Abstract][Full Text] [Related]
10. Safely promoting breast-conserving surgery and preventing early relapses with an aromatase inhibitor.
Markopoulos C
Surg Oncol; 2008 Aug; 17(2):113-28. PubMed ID: 18178077
[TBL] [Abstract][Full Text] [Related]
11. Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer.
Dodwell D; Williamson D
Cancer Treat Rev; 2008 Apr; 34(2):137-44. PubMed ID: 18006236
[TBL] [Abstract][Full Text] [Related]
12. Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials?
Tang SC
Cancer Invest; 2008 Jun; 26(5):481-90. PubMed ID: 18568770
[TBL] [Abstract][Full Text] [Related]
13. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Wardley AM
Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
[TBL] [Abstract][Full Text] [Related]
14. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
15. Cognitive impairments associated with breast cancer treatments: results from a longitudinal study.
Quesnel C; Savard J; Ivers H
Breast Cancer Res Treat; 2009 Jul; 116(1):113-23. PubMed ID: 18629633
[TBL] [Abstract][Full Text] [Related]
16. Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulators.
Dunn BK; Ryan A
Ann N Y Acad Sci; 2009 Feb; 1155():141-61. PubMed ID: 19250201
[TBL] [Abstract][Full Text] [Related]
17. Extending the benefits of adjuvant therapy in early HR+ breast cancer.
Goss PE
Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():45-52. PubMed ID: 18785006
[TBL] [Abstract][Full Text] [Related]
18. Hormonal therapy for advanced breast cancer.
Rugo HS
Hematol Oncol Clin North Am; 2007 Apr; 21(2):273-91. PubMed ID: 17512449
[TBL] [Abstract][Full Text] [Related]
19. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature.
Falleti MG; Sanfilippo A; Maruff P; Weih L; Phillips KA
Brain Cogn; 2005 Oct; 59(1):60-70. PubMed ID: 15975700
[TBL] [Abstract][Full Text] [Related]
20. Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer.
Lipton A; Leitzel K; Chaudri-Ross HA; Evans DB; Ali SM; Demers L; Hamer P; Brown-Shimer S; Pierce K; Gaur V; Carney W
J Clin Oncol; 2008 Jun; 26(16):2653-8. PubMed ID: 18443351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
